A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...

Please provide your email address to receive an email when new articles are posted on . Lung clearance index improved in month 3 and 12 of elexacaftor/tezacaftor ...

Please provide your email address to receive an email when new articles are posted on . Sweat chloride did not significantly differ between baseline and day 28 of triple therapy in this patient ...

A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...

Hundreds of people with cystic fibrosis are to be offered a new pill which has been hailed as “life changing” by health experts. Modulator drugs work by helping to make the CFTR protein work ...

SPL84 is administered directly into the lungs where it is taken up by the cells and is expected to drive the production of fully functional CFTR proteins. The Food and Drug Administration (FDA) has ...

Researchers conducted a phase 3b open-label trial at multiple sites in Australia and the European Union to assess the effect of elexacaftor-tezacaftor-ivacaftor, an approved medication for cystic ...

Bacteriophages (phages) are viruses that kill bacteria. Phage therapy used as an experimental therapy in 51 cystic fibrosis patients with multi-drug resistant infections showed that most had a ...

Monthly administration of liposome-delivered gene therapy for cystic fibrosis (CF) improved forced expiratory volume (FEV) in a randomized, double-blinded, placebo-controlled phase 2b clinical trial.

Scientists from the University of Liverpool have shown that phage therapy could offer a safe and effective alternative to antibiotics in the treatment of Cystic Fibrosis lung infections. Chronic lung ...

BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to continue the development of a gene editing therapy ...

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.